Orexo AB (ORX)

Currency in SEK
4.7
-0.2(-4.10%)
Closed·
Trading near 52-week Low
ORX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.75.0
52 wk Range
4.736.0
Key Statistics
Prev. Close
4.7
Open
4.9
Day's Range
4.7-5
52 wk Range
4.7-36
Volume
74.8K
Average Vol. (3m)
81.93K
1-Year Change
-83.5088%
Book Value / Share
4.80
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ORX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Orexo AB News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Orexo AB Earnings Call Summary for Q3/2026

  • Orexo posted Q3 continued operations revenue of SEK 0.8M with net loss of SEK 118M and negative cash flow of SEK 125M amid strategic shift.
  • Shares fell 7.1% to $5, near 52-week low, as company transitions from diversified drugmaker to AmorphOX platform-focused partnership model.
  • Normalized operating expenses at SEK 55M quarterly; management expects further cost reductions in 2027 as restructuring completes and Izipry development ends.
  • Izipry FDA resubmission targets Q1 2025 approval; OX640 pivotal trial starts Q4; rights issue expected to close Q4 2026 for added liquidity.
  • Cash position weakened to SEK 153M from SEK 277M prior quarter; company pursuing partnerships to extend runway beyond 2027 amid minimal revenue base.
Last Updated: 10/22/2026, 08:56 AM
Read Full Transcript
Orexo AB investor slides for Q3/2026
Orexo Q3 2026 slides
Last Update: Oct 22, 2026
See full investor slides

Earnings

Latest Release
Oct 22, 2026
EPS / Forecast
-2.10 / -2.10
Revenue / Forecast
4.5M / 4.5M
EPS Revisions
Last 90 days

ORX Income Statement

Compare ORX to Peers and Sector

Metrics to compare
ORX
Peers
Sector
Relationship
P/E Ratio
−0.4x109.6x−0.3x
PEG Ratio
0.00−1.360.00
Price / Book
1.0x4.1x2.6x
Price / LTM Sales
14.5x4.5x2.9x
Upside (Analyst Target)
-104.2%60.1%
Fair Value Upside
Unlock1.6%8.3%Unlock

Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabact UBT for the treatment of diagnosis of Helicobacter pylori. The company is developing Izipry for opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; OX390 for overdoses caused by a combination of life-threatening illicit drugs; OX125 for opioid overdose with powder-based nalmefene; OX472 for intranasal formulation of semaglutide, a GLP-1 receptor agonist, developed using proprietary AmorphOX technology; and develops thermostable and needle-free mucosal vaccines. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.

Employees
55
Market
Sweden

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1.80M4.88%9.21M
Other Institutional Investors
14.66M39.68%74.92M
Public Companies & Retail Investors
20.49M55.45%104.69M
Total
36.95M100.00%188.82M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Novo Holdings A/S26.10%9,643,18449,277
Avanza Fonder AB6.44%2,378,98812,157

FAQ

What Is the Orexo AB (ORX) Stock Price Today?

The Orexo AB stock price today is 4.7 SEK.

What Stock Exchange Does Orexo AB Trade On?

Orexo AB is listed and trades on the Stockholm Stock Exchange.

What Is the Stock Symbol for Orexo AB?

The stock symbol for Orexo AB is "ORX."

What Is the Orexo AB Market Cap?

As of today, Orexo AB market cap is 174.23M SEK.

What Is Orexo AB's Earnings Per Share (TTM)?

The Orexo AB EPS (TTM) is -12.63.

When Is the Next Orexo AB Earnings Date?

Orexo AB will release its next earnings report on Feb 04, 2027.

From a Technical Analysis Perspective, Is ORX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Orexo AB Stock Split?

Orexo AB has split 2 times.

How Many Employees Does Orexo AB Have?

Orexo AB has 55 employees.

What is the current trading status of Orexo AB (ORX)?

As of Oct 29, 2026, Orexo AB (ORX) is trading at a price of 4.7 SEK, with a previous close of 4.7 SEK. The stock has fluctuated within a day range of 4.7 SEK to 5.0 SEK, while its 52-week range spans from 4.7 SEK to 36.0 SEK.

What Is Orexo AB (ORX) Price Target According to Analysts?

The average 12-month price target for Orexo AB is 26.5 SEK, with a high estimate of 26.5 SEK and a low estimate of 26.5 SEK. 0 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +463.83% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.